To view this email as a web page, click here.

Does Maintenance Rucaparib Improve Post-Progression Outcomes in Ovarian Cancer?

Researchers tested maintenance therapy with rucaparib in a phase III trial of patients with recurrent epithelial ovarian cancer who experienced response to platinum-based chemotherapy.

Cladribine Plus Upfront Rituximab Shows Promise in Hairy Cell Leukemia

Researchers tested simultaneous vs delayed rituximab with cladribine in patients with hairy cell leukemia.

IN CASE YOU MISSED IT

Advanced Refractory RCC: TIVO-3 Results Presented for Tivozanib vs Sorafenib

Progression-free survival was compared for the VEGF TKI tivozanib vs sorafenib across multiple subgroups of refractory advanced renal cell carcinoma.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.